Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene-Editing Market, By Therapeutic Application (Oncology, Autoimmune or Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR or Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr or Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations and Others) - Industry Trends and Forecast to 2030.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene-Editing Market Analysis and Size
Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing is referred to as a genome editing technology that permits the genetic material to be added, altered and removed in an organism's DNA. CRISPR has revolutionized the field of gene therapy by enabling much more accurate gene editing and thus the prevention and treatment of human diseases. Key biomedical applications for CRISPR include gene therapy, drug discovery, and diagnostics. Various clinical studies on gene therapy are currently underway around the world.
Data Bridge Market Research analyses that the Clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing Market which was USD 1.09 billion in 2022, would reach up to USD 14.80 billion by 2030, and is expected to undergo a CAGR of 29.80% during the forecast period. “Oncology” dominates the therapeutic application segment of the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market owing to the higher prevalence of cancer. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene-Editing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapeutic Application (Oncology, Autoimmune or Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR or Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr or Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations and Others
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Applied StemCell (U.S.), ACEA BIO (U.S.), Synthego (U.S.), Thermo Fisher Scientific (U.S.), GenScript (China), Addgene (U.S.), Merck KGaA (Germany), Intellia Therapeutics, Inc. (U.S.), Cellectis (France), Precision Biosciences (U.S.), Caribou Biosciences, Inc. (U.S.), Transposagen Biopharmaceuticals, Inc. (U.S.), OriGene Technologies, Inc. (U.S.), Novartis AG (Switzerland), New England Biolabs (U.S.), Rockland Immunochemicals Inc. (U.S.), ToolGen, Inc. (South Korea), TAKARA BIO INC. (Japan), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), CRISPR Therapeutics AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
CRISPR gene editing is a revolutionary molecular tool that allows precise modification of an organism's DNA. It employs a guided RNA molecule to target specific genetic sequences, directing a protein called Cas9 to make changes such as adding, deleting, or replacing DNA segments. This technology has vast applications in medicine, biotechnology, and agriculture, enabling the correction of genetic mutations, development of new therapies, and creation of genetically modified organisms. CRISPR has transformed genetic research and holds promise for treating genetic diseases and advancing various industries.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene-Editing Market Dynamics
Drivers
- Advancements in Gene Editing Technology
Continuous improvements and innovations in CRISPR technology, such as the development of more precise and efficient Cas proteins, enhance its utility for a wide range of applications
- Potential for Treating Genetic Diseases
The ability to correct genetic mutations responsible for various diseases offers significant promise in the field of medicine, driving investment and research into CRISPR-based therapies
Opportunities
- Rising Therapeutic Applications
CRISPR can be used to treat genetic disorders by correcting or replacing faulty genes. Targeted gene editing can also help develop more effective cancer treatments. With the growing research activities in CRISPR technology, many therapeutic applications of it can be unravelled
- Drug Discovery and Development
CRISPR has the potential to accelerate the drug discovery process by creating disease models, screening for drug candidates, and validating drug targets
Restraint/Challenge
- High Development Cost
Developing CRISPR-based therapies or applications can be expensive, particularly in the early stages of research and development. High costs associated with CRISPR gene editing may challenge the market in the forecast period
This clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2022, Agilent Technologies Inc., a global leader in genomics technology, Leverages NVIDIA and AWS technology to improve analysis speeds of genomic bioinformatics pipeline
Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene-Editing Market Scope
The clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market is segmented on the basis of therapeutic application, application, technology, services, products and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapeutic Application
- Oncology
- Autoimmune or Inflammatory
Application
- Genome Engineering
- Disease Models
- Functional Genomics
- Others
Technology
- CRISPR or Cas9
- Zinc Finger Nucleases
- Others
Services
- Design Tools
- Plasmid and Vector
- Cas9 and g-RNA
- Delivery System Products
- Others
Products
- GenCrispr or Cas9 kits
- GenCrispr Cas9 Antibodies
- GenCrispr Cas9 Enzymes
- Others
End-Users
- Biotechnology and Pharmaceutical Companies
- Academic and Government Research Institutes
- Contract Research Organizations
- Others
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene-Editing Market Regional Analysis/Insights
The clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market is analysed and market size insights and trends are provided by therapeutic application, application, technology, services, products and end-user as referenced above.
The countries covered in the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market due to the considerable investments made by biotechnology and pharmaceutical companies. Furthermore, the rise in the healthcare infrastructure will further boost the growth of the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market in the region during the forecast period.
Asia-Pacific is projected to observe significant amount of growth in the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market due to the increasing of the per capita income. Moreover, the early accessibility of authorized therapies is further anticipated to propel the growth of the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene-Editing Market Share Analysis
The clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market.
Some of the major players operating in the clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing market are:
- Applied StemCell (U.S.)
- ACEA BIO (U.S.)
- Synthego (U.S.)
- Thermo Fisher Scientific (U.S.)
- GenScript (China)
- Addgene (U.S.)
- Merck KGaA (Germany)
- Intellia Therapeutics, Inc. (U.S.)
- Cellectis (France)
- Precision Biosciences (U.S.)
- Caribou Biosciences, Inc. (U.S.)
- Transposagen Biopharmaceuticals, Inc. (U.S.)
- OriGene Technologies, Inc. (U.S.)
- Novartis AG (Switzerland)
- New England Biolabs (U.S.)
- Rockland Immunochemicals Inc. (U.S.)
- ToolGen, Inc. (South Korea)
- TAKARA BIO INC. (Japan)
- Agilent Technologies, Inc. (U.S.)
- Abcam plc (U.K.)
- CRISPR Therapeutics AG (Switzerland)
SKU-